Metrics as of 10/15/2026, 05:33 PM (Berlin time), refresh in progress.
GeneDx Holdings Stock
GeneDx Holdings Corp.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Katherine A. Stueland
- Employees
- 1,300
- Market cap
- $2.1 B
- IPO
- 04/11/2020
GeneDx Holdings Corp. is a company specializing in the analysis of individual patient data within the Healthcare / Medical - Healthcare Information Services sector. Founded in 2015 by Eric Schadt and headquartered in Stamford, Connecticut, the firm utilizes advanced artificial intelligence and machine learning to…
AI-generated company profile based on the figures on this page, last updated on 05/08/2026. Not investment advice.
GeneDx Holdings stock: price history
1D
+4.2%
1W
+5.6%
1M
-24.5%
6M
+9.3%
YTD
-45.0%
1Y
-38.9%
2Y
+19.2%
5Y
-72.2%
10Y
–
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~118% stronger price swings than usual
GeneDx Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
2 more assignments (Enabler/Second row) Pro-only.
GeneDx Holdings Corp. is a specialized genomics company that provides genetic testing services for the diagnosis of rare diseases and pediatric examinations. The focus is on whole-exome and whole-genome sequencing. A key characteristic of the business model is the use of artificial intelligence and machine learning through its own technology platform for the analysis and clinical reporting of complex genomic data. Revenue is generated primarily through diagnostic tests, with processing handled through insurance companies, institutional customers, or self-pay patients. The company positions itself at the intersection of advanced information technology and personalized medicine.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about GeneDx Holdings
Analyst assessment of GeneDx Holdings
PRICE TARGET LOW
US$63.00
CONSENSUS
US$81.00
MEDIAN
US$84.00
PRICE TARGET HIGH
US$90.00
0
STRONG BUY
10
BUY
1
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 01/10/2026
GeneDx Holdings stock metrics
P/E
-19.59
P/B
8.68
EV/EBITDA
-29.23
RETURN ON EQUITY
-7.3%
NET MARGIN
-15.5%
DEBT/EQUITY
0.69
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.9%
FLOAT SHARES
28,897,167
AVG. DAILY VOLUME (30D)
726,436
Insider transactions (SEC)
Stueland Katherine
Stueland Katherine
Fuchs Thomas
Feeley Kevin
Feeley Kevin
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +4.2%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about GeneDx Holdings stock
What does GeneDx Holdings do?
GeneDx Holdings Corp. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Katherine A. Stueland, the company employs around 1,300 people.
The IPO was on 04/11/2020; the stock trades on NASDAQ under the ticker WGS.
What do analysts say about GeneDx Holdings stock?
11 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$81.00, ranging from US$63.00 to US$90.00, with a median of US$84.00.
This is an external assessment, not a statement by Market Jury.
When does GeneDx Holdings report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly 118% stronger than usual.
Does GeneDx Holdings pay a dividend?
No, GeneDx Holdings currently does not pay a dividend.
Which stocks are comparable to GeneDx Holdings?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get GeneDx Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess GeneDx Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.